Polak TB, van Rosmalen J, Uyl-de Groot CA. Expanded Access as a source of real-world data: an overview of FDA and EMA approvals. Br J Clin Pharmacol. 2020;86(9):1819-1826. https://doi.org/10.1111/bcp.14284 PMID:32200551 DOI: https://doi.org/10.1111/bcp.14284

Polak TB, Cucchi DGJ, van Rosmalen J, Uyl-de Groot CA. Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals. BMJ Open. 2022;12(1):e052186. https://doi.org/10.1136/bmjopen-2021-052186 PMID:34992108 DOI: https://doi.org/10.1136/bmjopen-2021-052186

Bunnik EM, Aarts N. The Role of Physicians in Expanded Access to Investigational Drugs: A Mixed-Methods Study of Physicians’ Views and Experiences in The Netherlands. J Bioeth Inq. 2021;18(2):319-334. https://doi.org/10.1007/s11673-021-10090-7 PMID:33590374 DOI: https://doi.org/10.1007/s11673-021-10090-7

Bunnik EM, Aarts N. What do patients with unmet medical needs want? A qualitative study of patients’ views and experiences with expanded access to unapproved, investigational treatments in the Netherlands. BMC Med Ethics. 2019;20(1):80. https://doi.org/10.1186/s12910-019-0420-8 PMID:31706313 DOI: https://doi.org/10.1186/s12910-019-0420-8

Tarantola A, Otto MH, Armeni P, Costa F, Malandrini F, Jommi C. Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case. J Pharm Policy Pract. 2023 May 17;16(1):67. https://doi.org/10.1186/s40545-023-00570-z PMID: 37198599 DOI: https://doi.org/10.1186/s40545-023-00570-z

Pham FY, Jacquet E, Taleb A, et al. Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019. Int J Cancer. 2022;151(8):1345-1354. https://doi.org/10.1002/ijc.34129 PMID:35603979 DOI: https://doi.org/10.1002/ijc.34129

Cogez F, Gervais M, Cardon SC, et al. Is an early access program for an oncology drug an asset in the French pricing and reimbursement pathway? Value in Health. 2022, POSB211 (https://www.valueinhealthjournal.com/article/S1098-3015(21)02494-3/pdf) (Accessed November 2023).

Jacquet E, Kerouani-Lafaye G, Grude F, et al. Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years. Eur J Cancer. 2021;149:82-90. https://doi.org/10.1016/j.ejca.2021.03.008 PMID:33838392 DOI: https://doi.org/10.1016/j.ejca.2021.03.008

Jommi C, Pantellini F, Stagi L, Verykiou M, Cavazza M. The economic impact of compassionate use of medicines. BMC Health Serv Res. 2021;21(1):1303. https://doi.org/10.1186/s12913-021-07255-w PMID:34863155 DOI: https://doi.org/10.1186/s12913-021-07255-w

Pilunni D, Navarra P. Compassionate drug uses in Italy. Analysis of regional and local diffusion. Ann Ist Super Sanita. 2023;59(1):43-50. PMID:36974704

Pilunni D, Daloisio V, Campopiano R, Pani M, Navarra P. Compassionate drug uses and saving for the national health system: the case study of Fondazione Policlinico Gemelli. Eur Rev Med Pharmacol Sci. 2021;25(20):6365-6377. PMID:34730218

Agenzia Italiana del Farmaco (AIFA) Farmaci uso compassionevole https://www.aifa.gov.it/farmaci-a-uso-compassionevole (Accessed November 2023).